AU2020248116B2 - Engineered adeno-associated (AAV) vectors for transgene expression - Google Patents

Engineered adeno-associated (AAV) vectors for transgene expression

Info

Publication number
AU2020248116B2
AU2020248116B2 AU2020248116A AU2020248116A AU2020248116B2 AU 2020248116 B2 AU2020248116 B2 AU 2020248116B2 AU 2020248116 A AU2020248116 A AU 2020248116A AU 2020248116 A AU2020248116 A AU 2020248116A AU 2020248116 B2 AU2020248116 B2 AU 2020248116B2
Authority
AU
Australia
Prior art keywords
aav
cell
aav9
brain
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020248116A
Other languages
English (en)
Other versions
AU2020248116A1 (en
Inventor
Killian S. HANLON
Eloise Marie HUDRY
Casey A. MAGUIRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Harvard University
Original Assignee
General Hospital Corp
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Harvard University filed Critical General Hospital Corp
Publication of AU2020248116A1 publication Critical patent/AU2020248116A1/en
Application granted granted Critical
Publication of AU2020248116B2 publication Critical patent/AU2020248116B2/en
Priority to AU2026201434A priority Critical patent/AU2026201434A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2020248116A 2019-03-28 2020-03-30 Engineered adeno-associated (AAV) vectors for transgene expression Active AU2020248116B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201434A AU2026201434A1 (en) 2019-03-28 2026-02-26 Engineered adeno-associated (AAV) vectors for transgene expression

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825703P 2019-03-28 2019-03-28
US62/825,703 2019-03-28
PCT/US2020/025720 WO2020198737A1 (en) 2019-03-28 2020-03-30 Engineered adeno-associated (aav) vectors for transgene expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201434A Division AU2026201434A1 (en) 2019-03-28 2026-02-26 Engineered adeno-associated (AAV) vectors for transgene expression

Publications (2)

Publication Number Publication Date
AU2020248116A1 AU2020248116A1 (en) 2021-10-14
AU2020248116B2 true AU2020248116B2 (en) 2025-12-04

Family

ID=72609527

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020248116A Active AU2020248116B2 (en) 2019-03-28 2020-03-30 Engineered adeno-associated (AAV) vectors for transgene expression
AU2026201434A Pending AU2026201434A1 (en) 2019-03-28 2026-02-26 Engineered adeno-associated (AAV) vectors for transgene expression

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201434A Pending AU2026201434A1 (en) 2019-03-28 2026-02-26 Engineered adeno-associated (AAV) vectors for transgene expression

Country Status (12)

Country Link
US (1) US20220195458A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947422A4 (cg-RX-API-DMAC7.html)
JP (2) JP7659271B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260036045A (cg-RX-API-DMAC7.html)
CN (1) CN113874387B (cg-RX-API-DMAC7.html)
AU (2) AU2020248116B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019436A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135292A1 (cg-RX-API-DMAC7.html)
IL (1) IL286725A (cg-RX-API-DMAC7.html)
MX (1) MX2021011701A (cg-RX-API-DMAC7.html)
SG (1) SG11202110165XA (cg-RX-API-DMAC7.html)
WO (1) WO2020198737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019200016A1 (en) 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
US11149256B2 (en) 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3959324B1 (en) 2019-04-26 2025-09-17 President and Fellows of Harvard College Aav vectors encoding mini-pcdh15 and uses thereof
AU2020366531A1 (en) * 2019-10-18 2022-05-26 Research Institute At Nationwide Children's Hospital Gene therapy targeting cochlear cells
FI4103214T3 (fi) 2020-02-13 2026-07-03 Tenaya Therapeutics Inc Geeniterapian vektorit sydänsairauden hoitoon
US12129287B2 (en) 2020-09-14 2024-10-29 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
US20240075167A1 (en) * 2021-02-03 2024-03-07 The Board Of Trustees Of The Leland Stanford Junior University Method of gene delivery to retinal astrocytes
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
TW202317768A (zh) 2021-07-08 2023-05-01 美商特納亞治療股份有限公司 用於基因療法的優化表現卡匣
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
CN114606264B (zh) * 2022-03-22 2025-08-26 三峡大学 一种用于神经系统药物递送的aav病毒载体
WO2024054864A1 (en) 2022-09-06 2024-03-14 Tenaya Therapeutics, Inc. Cardioprotective heart disease therapies
JP2026509271A (ja) 2023-03-10 2026-03-17 ダイノ セラピューティクス,インコーポレーテッド カプシドポリペプチドおよびその使用方法
EP4695396A1 (en) 2023-04-10 2026-02-18 Tenaya Therapeutics, Inc. Guide rnas, vectors, and virions for targeting mutations in the pln gene
WO2024215655A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
WO2024220545A2 (en) * 2023-04-17 2024-10-24 The General Hospital Corporation Aav capsids for on-target delivery to spinal cord
EP4698555A1 (en) * 2023-04-18 2026-02-25 uniQure biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
KR20260082361A (ko) 2023-08-31 2026-06-04 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026122963A1 (en) 2024-12-06 2026-06-11 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
WO2017136536A1 (en) * 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
WO2018022608A2 (en) * 2016-07-26 2018-02-01 Biomarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
WO2019169132A1 (en) * 2018-02-28 2019-09-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2547381T3 (es) * 2004-04-09 2015-10-05 Monsanto Technology, Llc Composiciones y procedimientos de control de infestaciones de insectos en plantas
US7588772B2 (en) * 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
NZ716102A (en) * 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3564379A1 (en) * 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
US10307492B2 (en) * 2014-03-11 2019-06-04 Wayne State University Modified MGLUR6 promoter and methods of use
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
GB2545763A (en) * 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
EP4219806A3 (en) 2017-04-11 2023-09-27 Ruprecht-Karls-Universität Heidelberg Adeno-associated virus library
US11512327B2 (en) * 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
MX2020001997A (es) * 2017-08-28 2020-07-20 Univ California Variantes de capside de virus adenoasociado y metodos de uso de estas.
CN109207520B (zh) * 2018-09-25 2022-05-10 北京锦篮基因科技有限公司 Leber遗传性视神经病变的基因药物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
WO2017136536A1 (en) * 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
WO2018022608A2 (en) * 2016-07-26 2018-02-01 Biomarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
WO2019169132A1 (en) * 2018-02-28 2019-09-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors

Also Published As

Publication number Publication date
US20220195458A1 (en) 2022-06-23
AU2026201434A1 (en) 2026-03-19
EP3947422A4 (en) 2023-05-17
JP7659271B2 (ja) 2025-04-09
KR102934700B1 (ko) 2026-03-09
WO2020198737A1 (en) 2020-10-01
BR112021019436A2 (pt) 2021-12-07
AU2020248116A1 (en) 2021-10-14
MX2021011701A (es) 2021-12-10
CA3135292A1 (en) 2020-10-01
KR20260036045A (ko) 2026-03-13
JP2025098107A (ja) 2025-07-01
KR20210143869A (ko) 2021-11-29
IL286725A (en) 2021-12-01
CN113874387B (zh) 2025-01-07
EP3947422A1 (en) 2022-02-09
JP2022527917A (ja) 2022-06-07
CN113874387A (zh) 2021-12-31
SG11202110165XA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CN113874387B (zh) 用于转基因表达的工程化腺相关病毒(aav)载体
RU2727672C2 (ru) Нацеливающие пептиды для направленной доставки аденоассоциированных вирусов (aav)
JP7303816B2 (ja) Aavベクター
US20240209394A1 (en) AAV Capsids and Uses Thereof
AU2008216018B2 (en) Mitochondrial nucleic acid delivery systems
US11118185B2 (en) AAV vectors for treatment of dominant retinitis pigmentosa
CN111621502B (zh) 视网膜劈裂蛋白的编码序列、其表达载体构建及其应用
CN103764831A (zh) 不含衣壳的aav载体、组合物以及制备载体和基因递送的方法
CN113840927A (zh) 用于治疗核纤层蛋白病的组合物及方法
RU2839774C2 (ru) Сконструированные аденоассоциированные (aav) векторы для экспрессии трансгена
JP2024517957A (ja) ベクター系
CN118159662A (zh) 用于治疗sod1相关疾病的crispr-cas13系统
Egorova et al. Adeno-associated virus vector-based gene therapy for hereditary diseases: Current problems of application and approaches to solve them
WO2025162267A1 (zh) 表达myo7a蛋白的双载体系统及其用途
Mason SRSF1-mediated gene therapy as a therapeutic approach for C9ORF72-related amyotrophic lateral sclerosis and fronto-temporal dementia (ALS-FTD)
WO2024165839A1 (en) Transgenes
Martin Development and Characterisation of HEK293T Cell Expression Systems for Enhanced Production of Recombinant AAV Viral Vectors
WO2024220545A2 (en) Aav capsids for on-target delivery to spinal cord

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)